DOI: 10.17044/scilifelab.13105229
title: Data from: Transcriptomic analysis reveals pro-inflammatory signatures associated with acute myeloid leukemia progression

description: <b>Data Set Description</b><b><br></b>

These data are
collected from a total of 70 participants (47 adult; 23 pediatric), all of
which had relapsed or primary resistant acute myeloid leukemia. The data, which
here are separated into an adult and a pediatric dataset, were generated as
part of a study by Stratmann et. al.
(https://doi.org/10.1182/bloodadvances.2021004962). The Stratmann et. al. study
is currently pre-published here: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2021004962/477210/Transcriptomic-analysis-reveals-pro-inflammatory Please note that
separate applications are necessary for the adult and pediatric dataset,
respectively. When applying for access, please indicate which of the datasets
that the application applies for. The adult dataset
contains transcriptome sequencing (RNA-seq) data from 25 diagnosis (D), 45
relapse (R1/R2/R3) and five (5) primary resistant (PR) leukemic samples from 47
patients, as well as five (5) normal CD34+ bone marrow control samples. The pediatric
dataset contains RNA-seq data from 18 diagnosis (D), 22 relapse (R1/R2), six
(6) persistent relapse (R1/2-P) and one (1) primary resistant (PR) leukemic
samples from 23 patients, as well as five (5) normal CD34+ bone marrow control
samples. The leukemic
samples originate from bone marrow or peripheral blood. The normal RNA samples
originate from purified CD34+ bone marrow cells from five different healthy
individuals. Further details regarding the samples are available in the
Supplemental Information part of Stratmann et. al.
(https://doi.org/10.1182/bloodadvances.2021004962). RNA-seq libraries
and associated next-generation sequencing were carried out by the SNP&SEQ
Technology platform, SciLifeLab, National Genomics Infrastructure Uppsala,
Sweden. Libraries were prepared using the TruSeq stranded total RNA library
preparation kit with ribosomal depletion by RiboZero Gold (Illumina). Sequencing
of adult samples was carried out on the Illumina HiSeq2500 platform, generating
paired-end 125bp reads using v4 sequencing chemistry. Sequencing of pediatric
samples was carried out on the Illumina NovaSeq6000 platform (S2 flowcell),
generating paired-end 100bp reads using the v1 sequencing chemistry. The CD34+
bone marrow control samples were sequenced using both platforms (Illumina
HiSeq2500 and NovaSeq6000). Further, all of
these acute myeloid leukemia samples have also been characterized by whole genome
sequencing or whole exome sequencing, with the datasets available under
controlled access through doi.org/10.17044/scilifelab.12292778. <b>Terms for access</b>The adult and
pediatric datasets are only to be used for research that is seeking to advance
the understanding of the influence of genetic and transcriptomic factors on
human acute myeloid leukemia etiology and biology. Use of the
protected pediatric dataset is only for research projects that can merely be
conducted using pediatric acute myeloid leukemia data, and for which the
research objectives cannot be accomplished using data from adults. Applications
intending various method development would thus not be considered as acceptable
for use of the pediatric dataset. Further, the pediatric dataset may not be
used for research investigating predisposition for acute myeloid leukemia based
on germline variants. 





































For conditional
access to the adult and/or pediatric dataset in this publication, please
contact datacentre@scilifelab.se